Syndax Pharmaceuticals Inc
$ 21.01
1.30%
31 Dec - close price
- Market Cap 1,826,081,000 USD
- Current Price $ 21.01
- High / Low $ 21.37 / 20.61
- Stock P/E N/A
- Book Value 1.33
- EPS -3.60
- Next Earning Report 2026-03-09
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.39 %
- ROE -1.29 %
- 52 Week High 22.73
- 52 Week Low 8.58
About
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, dedicated to developing cutting-edge therapies for cancer treatment. With a promising pipeline that includes innovative agents utilizing immuno-oncology and epigenetic modulation, Syndax aims to address significant unmet medical needs across a range of malignancies. The company is committed to advancing its clinical programs, seeking to enhance patient outcomes and solidify its position as a pivotal player in the rapidly evolving cancer therapeutics market.
Analyst Target Price
$39.31
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-03 | 2025-08-04 | 2025-05-06 | 2025-02-25 | 2024-11-05 | 2024-08-01 | 2024-05-08 | 2024-02-27 | 2023-11-02 | 2023-08-03 | 2023-05-08 | 2023-02-28 |
| Reported EPS | -0.7 | -0.83 | -0.9846 | -1.1 | -0.98 | -0.8 | -0.85 | -1 | -0.73 | -0.64 | -0.59 | -0.62 |
| Estimated EPS | -0.73 | -1.01 | -1.2734 | -0.2289 | -1.11 | -0.91 | -0.98 | -0.99 | -0.8 | -0.73 | -0.6 | -0.65 |
| Surprise | 0.03 | 0.18 | 0.2888 | -0.8711 | 0.13 | 0.11 | 0.13 | -0.01 | 0.07 | 0.09 | 0.01 | 0.03 |
| Surprise Percentage | 4.1096% | 17.8218% | 22.6794% | -380.5592% | 11.7117% | 12.0879% | 13.2653% | -1.0101% | 8.75% | 12.3288% | 1.6667% | 4.6154% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-09 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.5898 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SNDX
2025-12-24 10:09:48
Syndax Pharmaceuticals (NASDAQ:SNDX) has increased its debt significantly, holding US$343.9m at the end of September 2025, up from none a year prior. However, the company also boasts a strong cash position of US$454.2m, resulting in a net cash balance of US$110.3m. Despite operating at a loss, Syndax Pharmaceuticals demonstrated impressive revenue growth of 596% to US$111m, suggesting potential for improved free cash flow in the future.
2025-12-23 11:09:55
Syndax Pharmaceuticals (NASDAQ:SNDX) recently hit a new 52-week high of $21.50, trading above its 50- and 200-day moving averages with a market cap of $1.87 billion. The company reported a slight EPS beat in its most recent quarter but missed revenue estimates, remaining unprofitable. Analysts hold a "Moderate Buy" consensus rating with an average price target of $37.20, although Weiss Ratings maintains a "sell" recommendation.
2025-12-23 03:06:00
This article provides an in-depth analysis of Syndax Pharmaceuticals Inc. (NASDAQ: SNDX), highlighting a near-term neutral sentiment amidst stronger mid and long-term prospects. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide investors. The report emphasizes current signals, risk parameters, and opportunities for accessing real-time, institutional-grade analysis.
2025-12-21 09:09:44
Syndax Pharmaceuticals' FDA-approved menin inhibitor, Revuforj, recently received significant recognition at the 67th American Society of Hematology (ASH) Annual Meeting and was named Best New Drug at the 2025 Scrip Awards, boosting its clinical and reputational standing. While these accolades strengthen Revuforj's positioning and its recent FDA approval broadens its use, the company's investment narrative heavily relies on the success of just two assets, Revuforj and Niktimvo, to justify projected growth and address its current losses and premium valuation. Investors should consider this concentration risk despite the drug's rising visibility and significant forecasted revenue growth and upside to fair value.
2025-12-21 00:09:50
Syndax Pharmaceuticals has updated its corporate bylaws to allow for the electronic issuance of stock certificates. This change aims to modernize its administrative practices and align with contemporary digital standards for corporate governance.
2025-12-19 22:08:43
Syndax Pharmaceuticals has amended its bylaws to issue all new shares in uncertificated form, moving towards an electronic record-keeping system. Existing certificated shares will remain valid until surrendered. This change aims to streamline corporate administration and modernize shareholder documentation practices.
